Southwest Hospital

Running trials

• Recruiting

  A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

  NCT07406035· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

  NCT07509892· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

  NCT07498478· Phase 2· TransThera Sciences (Nanjing), Inc.· Source

• Recruiting

  Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

  NCT07317934· Phase 3· Innostellar Biotherapeutics Co.,Ltd· Source

• Recruiting

  Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

  NCT07266116· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Recruiting

  A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects With Moderate to Severe Diabetic Peripheral Neuropathy

  NCT07183761· Phase 2· Min Long· Source

• Recruiting

  A Prospective Cohort Study on Primary Cutaneous Amyloidosis

  NCT06998875· Phase 4· Army Medical University, China· Source

• Recruiting

  Modified Tumor-free Techniques Operation to Cervical Cancer

  NCT06836869· Peking Union Medical College Hospital· Source

• Recruiting

  A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B

  NCT06525909· Tongji Hospital· Source

• Recruiting

  Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer

  NCT05676190· ShiCang Yu· Source

• Active, not recruiting

  A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT05388669· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

  NCT04712643· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

  NCT03967977· Phase 3· BeiGene· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

  NCT03519230· Phase 3· BeiGene· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Diabetic neuropathy1 recruiting
• Hepatitis B1 recruiting
• Lupus (SLE)1 recruiting
• Macular degeneration1 recruiting
• Metastatic breast cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting

Closed trials

• Completed

  Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients

  NCT07294209· Phase 4· Southwest Hospital, China· Source

• Completed

  Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT05003245· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Photodynamic Therapy for Cholangiocarcinoma

  NCT04860154· Hepatopancreatobiliary Surgery Institute of Gansu Province· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

  NCT04924062· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

  NCT04716933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319· Phase 3· Merck Sharp & Dohme LLC· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Glioblastoma25 works · 0 trials
• Chronic spontaneous urticaria5 works · 0 trials